Lenalidomide in non-Hodgkin lymphoma: Biological perspectives and therapeutic opportunities

  • Kritharis A
  • Coyle M
  • Sharma J
 et al. 
  • 14

    Readers

    Mendeley users who have this article in their library.
  • 24

    Citations

    Citations of this article.

Abstract

Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration-approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in several additional lymphoma subtypes. There are many ongoing clinical trials examining the use of lenalidomide alone or in combinatorial therapy. It will be important in these studies to delineate reliable, predictive biomarkers to optimally integrate lenalidomide into lymphoma treatment paradigms.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Athena Kritharis

  • Michael Coyle

  • Jaya Sharma

  • Andrew M. Evens

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free